Chantal Pharand, B.Pharm., Pharm.D.
- Pharmacienne, Hôpital du Sacré-Cœur de Montréal
- Professeure titulaire et Vice-doyenne aux études, Faculté de pharmacie, Université de Montréal
Téléphone : 514 338-2222, poste 2506
Télécopieur : 514 338-2694
Formation et titres de compétences
- Pharm.D., Philadelphia College of Pharmacy and Science, Philadelphie, PA, 1991
- Baccalauréat (pharmacie), Université de Montréal, Montréal, 1989
Domaine, thèmes et intérêts de recherche
Circulation coronarienne, pharmacodynamie des antiplaquettaires, facteurs de risques et maladies coronariennes.
Prix et distinctions
2007 Prix Pharmacien de cœur et d’action en recherche
Publications
Articles :
Lordkipanidzé M, Diodati JG, Pharand C. Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: A look at the clinical and pharmacological evidence. Pharmacol Ther 2009; doi:10.1016/j.pharmthera.2009.03.019. (IF 8.36)
Lordkipanidzé M, Diodati JG, Schampaert E, Palisaitis DA, Pharand C. Prevalence of unresponsiveness to aspirin and/or clopidogrel in patients with stable coronary heart disease. Am J Cardiol 2009; 104:1189-93. (IF 3.60)
Nguyen TA, Lordkipanidzé M, Diodati JG, Palisaitis DA, Schampaert E, Turgeon J, Pharand C. Week-long high-maintenance dose clopidogrel regimen achieves better platelet aggregation inhibition than a standard loading dose before percutaneous coronary intervention; results of a double blind, randomized clinical trial. J Interv Cardiol 2009; 22: 368-77. (IF to come in 2009)
Lordkipanidzé M, Pharand C, Palisaitis DA, Schampaert E, Diodati JG. Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel. Thromb Res 2009;124:546-53. doi:10.1016/j.thromres.2009.04.003. (IF 3.032)
Lordkipanidzé M, Pharand C, Schampaert E, Palisaitis DA, Diodati JG. Evaluation of the platelet count drop method for assessment of platelet function in comparison with “gold standard” light transmission aggregometry. Thromb Res 2009;124:418-22. (IF 2.449)
Lordkipanidzé M, Diodati JG, Turgeon J, Schampaert E, Palisaitis DA, Pharand C. Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin. Int J Cardiol 2009. (IF 2.878) [sous presse]
Lordkipanidzé M, Pharand C, Nguyen TA, Schampaert E, Palisaitis DA, Diodati JG. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 2008; 29: 2877-85. (IF 7.924)
Lordkipanidzé M, Pharand C, Nguyen TA, Schampaert E, Diodati JG. Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition. Ther Drug Monit 2008;30:372-8. (IF 3.03)
Lordkipanidzé M, Pharand C, Diodati JG. Comparison of different methods of measurement of aspirin resistance: using the appropriate statistic: reply [letter]. Eur Heart J 2008; 29:138-139. (IF 7.34)
Lordkipanidzé M, Pharand C, Palisaitis DA, Turgeon J, Schampaert E, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702-8. (IF 7.34)
Chapitres de livres :
Pharand C, Williamson D. Dyslipidémies. In: Gimenez F, Brazier M, Calop J, Dine T, Tchiakpe L, eds. Pharmacie Clinique et Thérapeutique. 2008: Masson, Paris, France. 1232 p.
